7	Lange, et al	2005	Germany	Case-control	Cases: 10 Controls: 20	3 3	**Association of CD14 genotype with atopic dermatitis** Children without atopic dermatitis (%): CC 4 (13.3); CT 13 (43.3); TT 3 (10.0); Total 20 (66.6) Children with atopic dermatitis: CC 5 (16.7); CT 1 (3.3); TT 4 (13.3); Total 10 (33.3) Total (%): CC 9 (30); CT 14 (46.7) (p=0.017); TT 7 (23.3); Total 30 (100)
8	Weidinger, et al.	2005	Germany	Cross-sectional	Total: 866/1009 (M/F) AD: 242 (12.9%)	49.0	No significant associations between AE and any single polymorphism or haplotype of *CARD15*.
9	Weidinger, et al	2005	Germany	Case-control	Total: 185/269 (M/F)	44.17	**NOD1 haplotypes, haplotype frequencies with 95% CIs and association results** KORA S4: Haplotype / Frequency / 95% CI / Association G-A-T-G-G-T-A-T-A-C-A: 0.04093; 0.02801; 0.05385; NS A-G-T-G-G-T-A-T-A-C-A: *; NS A-G-T-G-G-T-A-T-A-C-G: 0.07809; 0.06059; 0.09559; NS G-A-T-A-C-C-G-T-A-C-G: 0.43251; 0.40020; 0.46483; NS A-G-T-A-C-C-G-T-A-C-G: 0.05985; 0.04438; 0.07532; AE, OR=0.12; *P* =.003 G-A-C-A-C-C-G-C-G-T-G: 0.16114; 0.13716; 0.18512; NS A-G-T-G-G-T-A-T-G-T-G: 0.03044; 0.01924; 0.04165; NS
10	Fölster-Holst, et al	2005	Germany	Case-control	Cases: 201 Controls: 368		**Case-control association of SPINK5 Asn368Ser, Asp386Asn and Glu420Lys alleles** Variant / Cases (n= 201) 1-1 / 1-2 / 2-2 / Healthy controls (n= 368) 1-1 / 1-2 / 2-2 / Global χ^2 / P-value / OR(95% CI) Asn368Ser: 41 (0.20); 106 (0.52); 54 (0.26); 90 (0.24); 196 (0.53); 81 (0.22); 2.25; 0.32; 0.94 (0.66-1.07) Asp386Asn: 4 (0.02); 31 (0.15); 168 (0.82); 5 (0.03); 72 (0.20); 291 (0.78); 1.86; 0.24; 0.85 (0.57-1.18) Glu420Lys: 42 (0.21); 106 (0.53); 51 (0.26); 90 (0.25); 195 (0.53); 82 (0.22); 0.77; 0.37; 0.89 (0.69-1.14)
11	Novak, et al	2005	Germany	Case-control	Cases: 225 Controls: 175	30.8 41.0	**Results of association analyses of subtypes of AE with *IL 18* SNPs** Groups 1,2, and 3 vs group 4 / Trend test / Odds ratio / Confidence interval of the odds ratios Exon 1, 113G: 0.0011; 2.7627; 0.9071-8.4140 Exon 1, 127T: 0.0011; 2.7731; 0.9107-8.4441 Promoter 1, – 137C: 0.0001; 4.2821; 1.2413-14.7716 Promoter 2, – 132G: 0.5585; 0.386; 0.1114-1.3400 Promoter 2, – 133G: 0.0111; 1.7426; 0.8116-3.7416
12	Hosomi, et al	2005	Japan	Case-control	Cases: 114 Controls: 89	28.6 33.0	**Allele and genotypes frequency of a polymorphism in the intragenic region between SLC9A3R1 and NAT9** Polymorphism / Allele / Atopic dermatitis n (%) / Normal control n (%) / P-value G / A: G 181 (79); 145 (81); NS A 47 (21); 33 (19)
13	Tsunemi, et al	2004	Japan	Case-control	Cases: 137/56 (M/F) Controls: 89/69 (M/F)	27.4 (11-61) 24.2 (18-82)	**Genotype and allele frequencies of the −431C>T single-nucleotide polymorphism of TARC gene in atopic dermatitis (AD) patients and controls** AD (n= 193) / Control (n= 158) / P Genotype C/C: 61 (31.6); 61 (38.6); 0.38 C/T: 106 (54.9); 79 (50.0) T/T: 26 (13.5); 18 (11.4) Allele C: 228 (59.1); 201 (63.6); 0.22 T: 158 (40.9); 115 (36.4)

14	Tsunemi, et al	2004	Japan	Case-control	Cases: 139/59 (M/F) Controls: 104/79 (M/F)	27.4 (11-61) 29.2 (18-82)	**Genotype frequencies of C1014T SNP of CCR4**

Genotype	AD (n= 198)	Control (n= 183)	P value
C/C	188 (94.9)	173 (94.5)	0.58
C/T	9 (4.5)	10 (5.5)	
T/T	1 (0.5)	0 (0.0)	

15	Vasilopoulos, et al	2004	UK	Case-control	Cases: 103 Controls: 261

Allelic distribution of the SCCE AACC insertion

	AACC	Heterozygotes	AACC AACC	Total
Control	**96**	**105**	**60**	**261**
	29	**32**	**42**	**103**
Atopic dermatitis	**OR (95% CI)**	**p-value**	**Analysis performed**	
OR_{HET}	1.01 (0.57, 1.79)	NS	—	
OR_{HOM}	2.32 (1.31, 4.11)	0.0037	—	
$OR_{OVERALL}$	2.31 (1.42, 3.76)	0.0007	Trend (recessive model)	
$OR_{OVERALL}$	1.48 (0.90, 2.44)	NS	Carriage (dominant model)	

16	Hosomi, et al	2004	Japan	Case-control	Cases: 101 Controls: 75

28.2 (7-72)
33.7 (19-71)

Association study of IL4R promoter polymorphism

Polumorphism			Atopic dermatitis n	Atopic dermatitis (%)	Normal control n	Normal control (%)	P-value
−3112C >T	Allele	C	64	(32)	69	(46)	
		T	138	(68)	81	(54)	0.0075
	Genotype	CC	14	(14)	14	(19)	
		CT	36	(36)	41	(55)	
		TT	51	(50)	20	(26)	0.0018
−1803T >C	Allele	T	42	(21)	53	(35)	
		C	160	(79)	97	(65)	0.0034
	Genotype	TT	4	(4)	8	(11)	
		TC	34	(34)	37	(49)	
		CC	63	(62)	30	(40)	0.0038
−327C >A	Allele	C	29	(14)	46	(31)	
		A	173	(86)	104	(69)	0.00033
	Genotype	CC	3	(3)	8	(11)	
		CA	23	(23)	30	(40)	
		AA	75	(74)	37	(49)	0.00086
−326A >C	Allele	A	40	(20)	51	(34)	
		C	162	(80)	99	(66)	0.0031
	Genotype	AA	4	(4)	9	(12)	
		AC	32	(32)	33	(44)	
		CC	65	(64)	33	(44)	0.009
−186G >A	Allele	G	40	(20)	51	(34)	
		A	162	(80)	99	(66)	0.0031
	Genotype	GG	4	(4)	9	(12)	
		GA	32	(32)	33	(44)	
		AA	65	(64)	33	(44)	0.009
−184A >G	Allele	A	183	(91)	137	(91)	NS
		G	19	(9)	13	(9)	
	Genotype	AA	84	(83)	63	(84)	NS
		AG	15	(15)	11	(15)	
		GG	2	(2)	1	(1)	

Frequency of proximal promoter haplotypes

Haplotype	AD n (%)	control n (%)	P value	Pc value
α	162 (80)	99 (66)	0.0031	0.0093
β	29 (14)	46 (31)	0.00033	0.00099
γ	11 (6)	5 (3)	NS	NS

–327C>A, –326A>C, –186G>A, and –184A>G, appeared to form three haplotypes : α (…AC… A.A), β (…CA…G.A…), and γ (…AA…G.A).

17	Ahmad-Nejad, et al	2004	Germany	Case-control	Cases: 78 Controls: 39	29 (14-78) 32 (17-58)	**Frequencies of TLR-2 and TLR-4 SNPs** Cases: TLR-2 R753Q 9 (11.5); TLR-4 D299G T399I 9 (12.0); TLR-2 or TLR-4 18 (23.5) Controls: 1 (2.5); 2 (5.0); 2 (5.0) P=0.01
18	Hoffjan, et al	2004	USA	Cohort	Total: 207	0	A borderline significant relationship between the *CD14* -159T allele and AD in the first year.
19	Kabesch, et al	2004	Germany	Cross-sectional	Total: 560/588 (M/F)	9.5	**SPINK5 G1258A polymorphism** SPINK5: AD = no association; Asthma + AD = 4.56 (1.37-15.12)
20	Yang, et al	2004	Taiwan	Cross-sectional	Total: 667/666 (M/F)	19-49	IL-4 promater : no relation, CTLA-4 : no relation
21	Vavilin, et al	2003	Russia	Case-control	Cases: 126 Controls: 199	1-15 1-15	**Distribution of Alleles and Genotypes of GST in Children**

Parameter	Control		AD
	nonatopic	randomized	
Allele frequency			
GSTM1*0	0.643	0.624	0.661
GSTM1*1	0.357	0.376	0.339
GSTT1*0	0.333	0.436	0.512 ($p<0.001$)
GSTT1*1	0.667	0.564	0.488
GSTP1-Ile_{105}	0.651	0.695	0.691
GSTP1-Val_{105}	0.349	0.305	0.309
Genotypes			
GSTM1*0/0	0.414 (41)	0.39 (39)	0.437 (55)
GSTM1+	0.586 (58)	0.61 (61)	0.563 (71)
GSTT1*0/0	0.111 (11)	0.19 (19)	0.262 (33)
GSTT1+	0.889 (88)	0.81 (81)	0.738 (93)
GSTP1 Ile_{105}/Ile_{105}	0.333 (33)	0.483 (50)	0.461 (59)
GSTP1 Ile_{105}/Val_{105}	0.637 (63)	0.424 (39)	0.453 (56)
GSTP1 Val_{105}/Val_{105}	0.03 (3)	0.093 (11)	0.086 (11)

Associations of Haplotypes with Predisposition to AD

Haplotype	Frequency in groups		OR (CI)
	AD	nonatopic control	
M1"+"/T1"+"/P1 Ile/Val	25	17	1.0
M1"+"/T1"+"/P1 Ile/Ile	23 (p=0.149)	31	1.98 (0.81-4.89)
M1"+"/T1"+"/P1 Val/Val	6 (p=0.163)	3	2.7 (0.50-18.13)
M1"+"/T1"0/0"/P1 Ile/Ile	7 (p=0.054)	2	4.72 (0.78-49.47)
M1"+"/T1"0/0"/P1 Ile/Val	10 (p=0.163)	5	2.7 (0.71-11.33)
M1"+"/T1"0/0"/P1 Val/Val	0 (p=0.68)	0	1.35 (0.02-109.16)
M1"0/0"/T1"+"/P1 Ile/Ile	20 (p=0.159)	13	2.07 (0.79-5.52)
M1"0/0"/T1"+"/P1 Ile/Val	15 (p=0.85)	24	0.84 (0.33-2.12)
M1"0/0"/T1"+"/P1 Val/Val	4 (p=0.07)	0	6.74 (0.68-163.29)
M1"0/0"/T1"0/0"/P1 Ile/Ile	7 (p=0.021)	1	9.43 (1.06-438.6)
M1"0/0"/T1"0/0"/P1 Ile/Val	8 (p=0.067)	3	3.59 (0.74-22.89)
M1"0/0"/T1"0/0"/P1 Val/Val	1 (p=0.41)	0	2.7 (0.17-80.32)

22	Hummelshoj, et al	2003	Denmark	Case-control	Cases: 55 Controls: 104	

Genotype frepuencies and P-values based on 2 × 3 tables of the IL-13−1024 polymorphism

Genotype	NA-Controls (n=104)	AD-P (n=55)
CC	76 (73%)	28 (51%)
CT	26 (25%)	25 (45%)
TT	2 (2%)	2 (4%)
p		2.0E-02

Odds ratios for the IL-13−1024 marker

Cases/controls	C-positive vs.rest		T-positive vs.rest	
	OR	Fisher	OR	Fisher
AD-P/NA-Controls	0.52	4.3E-01	2.62	4.6E-03

23	Tsunemi, et al	2003	Japan	Case-control	Cases :142/59 (M/F) Controls: 103/79 (M/F)	27.4 (11-61) 29.1 (18-82)

Allele and genotype frepuencies of CCR3 in AD patients and controls and subjects

Allele	AD (n=201)	Control (n=182)	P	Genotype	AD (n=201)	Control (n=182)	P
T	389 (96.8)	353 (97.0)	0.87	T/T	188 (93.5)	171 (94.0)	0.86
C	13 (3.2)	11 (3.0)		T/C	13 (6.5)	11 (6.0)	
				C/C	0 (0.0)	0 (0.0)	

24	Yamamoto, et al	2003	Japan	Case-control	Cases: 265/186 (M/F) Controls: 50/66 (M/F)	24 (13-69) 35 (22-55)

IL5−703 polymorphism in atopic dermatitis (AD) patients classified by blood eosinophil levels

Subjects	Eosinophil (%)	n	Allele frequency			IL5−703C/T genotype				
			C	T	P value	CC	CT	TT	P value	
Controls		116	99 (43%)	133 (57%)		23 (20%)	53 (46%)	40 (34%)		
Total AD patients		451	403 (45%)	499 (55%)	0.5832	88 (20%)	227 (50%)	136 (30%)	0.6175	
	< 7	203	173 (43%)	233 (57%)	0.9879	34 (17%)	105 (52%)	64 (31%)	0.5678	
	7-15	178	155 (44%)	201 (56%)	0.8357	0.7962	33 (19%)	89 (50%)	56 (31%)	0.7681	0.8921
	> 15	70	75 (54%)	65 (46%)	0.0412	0.0247	21 (30%)	33 (47%)	16 (23%)	0.1430	0.0476

IL5−703 polymorphism in AD patients classified by serum IgE concentration

Subjects	Serum IgE (IU/ml)	n	Allele frequency			IL5−703C/T genotype				
			C	T	P value	CC	CT	TT	P value	
Controls		116	99 (43%)	133 (57%)		23 (20%)	53 (46%)	40 (34%)		
Total AD patients		451	403 (45%)	499 (55%)	0.5832	88 (20%)	227 (50%)	136 (30%)	0.6175	
	< 500	144	110 (38%)	178 (62%)	0.3005	18 (13%)	74 (51%)	52 (36%)	0.2641	
	500-2000	93	83 (45%)	103 (55%)	0.6893	0.1642	16 (17%)	51 (55%)	26 (28%)	0.4159	0.3429
	> 2000	214	210 (49%)	218 (51%)	0.1161	0.0041	54 (26%)	102 (47%)	58 (27%)	0.3036	0.0088

25	Safronova, et al	2003	Russia	Case-control	Cases: 117 Controls: 157	

Relative Risk of Asthma and Dermatitis in Children with Various GSTP1 Genotypes

Genotype, disease		Total	Nonsmokers	Passive smokers
GSTP1 Ile/Val	BA	0.69 (0.39-1.22)	0.78 (0.28-2.15)	0.64 (0.32-1.30)
	AD	0.51 (0.28-0.92)	0.3 (0.10-0.85)	0.75 (0.35-1.60)
GSTP1 Ile/Ile	BA	1.24 (0.70-2.22)	1.09 (0.38-3.10)	1.35 (0.66-2.70)
	AD	1.55 (0.85-2.81)	2.76 (0.98-7.95)	0.98 (0.45-2.10)
GSTP1 Val/Val	BA	2.37 (0.59-13.70)	2.32 (0.2-118.1)	2.37 (0.4-24.7)
	AD	3.22 (0.81-18.40)	2.32 (0.2-128.4)	3.73 (0.7-37.9)

26	Brocvielle, et al	2003	France	Case-control	Cases: 11/9 (M/F) Controls: 11/9 (M/F)	22-59 20-54

Distribution of acetylator phenotypes and genotypes

	Atopic dermatitis (n=20)		Volunteers (n=20)		Total (n=40)	
	n	%	n	%	n	%
RA phenotype (rapid)	11	55	12	60	23	57.5
SA phenotype (slow)	8	40	8	40	16	40
IA phenotype (intermediate)	1	5	0	0	1	2.5
Total	20	100	20	100	40	100
Homozygous RA						
*NAT2*4/NAT2*4*	2	10	2	10	4	10
Heterozygous RA						
*NAT2*4/NAT2*5*	6	30	6	30	12	30
*NAT2*4/NAT2*6*	3	15	4	20	7	17.5
*NAT2*4/NAT2*7*	0	0	0	0	0	0
Total (RA)	11	55	12	60	23	57.5
Homozygous SA						
*NAT2*5/NAT2*5*	0	0	1	5	1	2.5
*NAT2*6/NAT2*6*	2	10	2	10	4	10
Heterozygous SA						
*NAT2*5/NAT2*6*	6	30	5	25	11	27.5
*NAT2*5/NAT2*7*	1	5	0	0	1	2.5
*NAT2*6/NAT2*7*	0	0	0	0	0	0
Total (SA)	9	45	8	40	17	42.5
Total (RA + SA)	20	100	20	100	40	100

27	Rafatpanah, et al	2003	UK	Case-control	Cases: 64/49 (M/F) Controls: 72/42 (M/F)	4 (3-10) 11 (9-13)

Allele and genotype frepuencies of GM-CSF polymorphisms

	Total population			
	Control	AD	OR	P value
GM-CSF –677	63	113		
Alleles				
A	63 (50%)	161 (71%)	2.3 (1.4-3.6)	<.001
C	63 (50%)	65 (29%)	1.0	
Genotype				
AA	10 (16%)	54 (48%)	7.5 (2.2-25)	<.001
AC	43 (68%)	53 (47%)		
CC	10 (16%)	6 (5%)	1.0	
GM-CSF –1916	62	104		
Alleles				
T	64 (52%)	144 (69%)	1.9 (1.2-3.1)	.001
C	60 (48%)	64 (31%)	1.0	
Genotype				
TT	12 (19%)	49 (47%)	3.3 (1.5-7.2)	<.001
TC	40 (65%)	46 (44%)		
CC	10 (16%)	9 (9%)	1.0	

Allele and genotype frequencies of TNF-α and IL-1β polymorphisms

	Total population		
	Control	AD	P value
TNF-α(−308)	71	113	
Alleles			
A	32 (23%)	37 (16%)	.1
G	110 (77%)	189 (84%)	
Genotype			
AA	2 (3%)	5 (4%)	.08
AG	28 (39%)	27 (24%)	
GG	41 (58%)	81 (72%)	
IL-1β	112	109	
Alleles			
X	43 (19%)	50 (23%)	.4
O	181 (81%)	168 (77%)	
Genotype			
XX	4 (4%)	10 (9%)	
XO	35 (31%)	30 (28%)	.8
OO	73 (65%)	69 (63%)	

28 He, et al. 2003 Canada Cohort Total: 368 birth

Prevalence of atopy and atopic diseases at 24 months of age in different genotype groups

Phenotype	IL13Arg130Gln			IL13C−1112T			IL4C−589T		
	Arg/Arg	Arg/Gln	Gln/Gln	CC	CT	TT	CC	CT	TT
Probable asthma	7 (12/182)	9 (8/85)	14 (2/14)	7 (13/181)	9 (8/93)	11 (1/9)	6 (12/198)	13 (10/78)	8 (1/12)
Rhinitis without colds	14 (25/182)	7 (6/85)	21 (3/14)	14 (25/181)	9 (8/93)	0 (0/9)	10 (20/198)	9 (7/78)	33[a] (4/12)
Atopic dermatitis	6 (11/179)	16 (14/85)	7[b] (1/14)	9 (16/180)	11 (10/91)	0 (0/9)	8 (15/197)	13 (10/76)	17 (2/12)
Positive skin test	9 (17/182)	17 (14/83)	21[c] (3/14)	11 (19/180)	16 (15/92)	0 (0/9)	12 (23/197)	13 (10/77)	17 (2/12)

[b]Relative risk Gln/Gln and Arg/Gln vs Arg/Arg=2.5 (95% CI=1.2-5.2, P=0.014).
[c]Relative risk Gln/Gln and Arg/Gln vs Arg/Arg=1.9 (95% CI=1.0-3.5, P=0.047).
[a]Relative risk TT vs CT and CC=3.4 (95% CI=1.4-8.2, P=0.010).

29 Reich, et al 2003 Germany Case-control Cases: 44/50 (M/F) 26.0 (6-63)
Controls: 125/89 (M/F) 34.0 (18-82)

Genotype frequencies in the investigated groups

		Atopic dermatitis (n=94)		Controls (n=214)			
Locus	Genotype	n	(%)	n	(%)	OR	(95% CI)
TNFA —238	G/G	86	(91.49)	195	(91.12)		
	G/A	7	(7.45)	18	(8.41)	1.02	(0.42-2.31)
	A/A	1	(1.06)	1	(0.47)	1.05	(0.17-5.33)
TNFA −308	G/G	68	(72.34)	158	(73.83)		
	G/A	25	(26.60)	56	(26.17)	1.13	(0.64-1.98)
	A/A	1	(1.06)	0	(0.00)	1.28	(0.41-3.93)
IL10 −1082	A/A	18	(19.15)	49	(22.90)		
	A/G	53	(56.38)	118	(55.14)	1.15	(0.79-1.69)
	G/G	23	(24.47)	47	(21.96)	1.32	(0.62-2.85)
IL6 −174	C/C	19	(20.21)	44	(20.56)		
	C/G	48	(51.06)	104	(48.60)	0.97	(0.67-1.38)
	G/G	27	(28.72)	66	(30.84)	0.93	(0.45-1.91)
IL1B −511	C/C	36	(38.30)	94	(43.93)		
	C/T	48	(51.06)	102	(47.66)	1.21	(0.81-1.81)
	T/T	10	(10.64)	18	(8.41)	1.47	(0.66-3.26)
IL1B +3953	T/T	51	(54.26)	123	(57.48)		
	T/C	39	(41.49)	75	(35.05)	1.00	(0.66-1.51)
	C/C	4	(4.25)	16	(7.47)	1.00	(0.43-2.27)
IL1RN	1/1	39	(41.48)	105	(49.07)		
	1/2	41	(43.62)	76	(35.51)	1.05	(0.81-1.34)
	1/3,5	4	(4.26)	8	(3.74)	1.10	(0.66-1.80)
	2/2	10	(10.64)	22	(10.28)	1.15	(0.54-2.42)
	2/3	0	(0.00)	3	(1.40)	1.21	(0.44-3.25)

30	Tamura, et al	2003	Japan	Case-control	Cases: 47 Controls: 66	
31	Kato, et al	2003	Japan	Case-control	Cases: 124 Controls: 110	28.7 (7-74) 35.0 (19-71)

Association between 2964G/A variant of STAT6 gene and allergic subjects

Group	No.	STAT6 2964G/A		
		AA+GA	GG (without A allele)	
Control subjects	66	44	22	
Allergic subjects	102	62	40	0.2724
Atopic dermatitis	47	34	13	0.3327
Bronchial asthma	73	41	32	0.1369
Food-related anaphylaxis	14	10	4	0.4974

Allele and genotype frequency of SPINK5 polymorphisms

	AD		Controls		
Polymorphism	n	(%)	n	(%)	P-value
IVS12-26C→T					
Allele					
C	145	(62)	111	(53)	NS
T	89	(38)	97	(47)	
Genotype					
CC	41	(35)	31	(30)	NS
CT	63	(54)	49	(47)	
TT	13	(11)	24	(23)	0.020
IVS12-10A→G					
Allele					
A	144	(62)	111	(53)	NS
G	88	(38)	97	(47)	
Genotype					
AA	41	(35)	31	(30)	NS
AG	62	(54)	49	(47)	
GG	13	(11)	24	(23)	0.029
1103A→G (Asn368Ser)					
Allele					
A	89	(38)	95	(46)	NS
G	145	(62)	111	(54)	
Genotype					
AA	13	(11)	23	(22)	0.029
AG	63	(54)	49	(48)	
GG	41	(35)	31	(30)	NS
1156G→A (Asp386Asn)					
Allele					
A	113	(48)	109	(52)	NS
G	121	(52)	99	(48)	
Genotype					
AA	26	(22)	30	(29)	NS
AG	61	(52)	49	(47)	
GG	30	(26)	25	(24)	NS
1188T→C (His369His)					
Allele					
T	145	(62)	111	(53)	NS
C	89	(38)	97	(47)	
Genotype					
TT	41	(35)	31	(30)	NS
TC	63	(54)	49	(47)	
CC	13	(11)	24	(23)	0.020
1258G→A (Glu420Lys)					
Allele					
G	94	(39)	100	(45)	NS
A	148	(61)	120	(55)	
Genotype					
GG	11	(9)	22	(20)	0.023
AG	72	(59)	56	(51)	
AA	38	(32)	32	(29)	NS

32	Kabesch, et al	2003	Germany	Cross-sectional	Total: 1872	9-11	**Association between CARD15 polymorphisms and atopic diseases**

Polymorphism	Atopic dermatitis (n=330/1747)
C2104 (Arg675Trp) (n=202/1805)	16.2% vs 18.5% NS
G2722C (Gly881Arg) (n=73/1805)	29.6% vs 18.5% 1.85 (1.10-3.13)
3020iC (n=132/1805)	23.0% vs 18.5% NS

33	Sengler, et al	2003	Germany	Nested case-control	Cases: 184 Controls: 119	7 7	**CD14 genotype frequencies**

Phenotype	n	Genotype (frequencies) -159CC	-159CT	-159TT
1.Asthma	84	0.27	0.51	0.21
2.Allergic rhinitis	80	0.20	0.58	0.23
3.Atopic dermatitis	184	0.26	0.52	0.22
4.Polysensitization age 7years	78	0.30	0.45	0.26
5.Polysensitization age 10years	89	0.28	0.46	0.26
6.IgE>85.percentile at ≥ two time-points	78	0.28	0.47	0.24
7.IgE<15.percentile at ≥ two time-points	77	0.33	0.51	0.17
8.Non-atopic countrols	119	0.22	0.61	0.18

34	Tsunemi, et al	2002	Japan	Case-control	Cases: 130/55 (M/F) Controls: 102	27.6 (11-61)	**Allele and genotype frequencies of IL-13 polymorphisms in AD patients and control subjects**

SNPs	AD	Control	P value		AD	Control	P value
A704C							
A	236 (63.8)	141 (69.1)	0.20	A/A	72 (38.9)	52 (51.0)	0.083
C	134 (36.2)	63 (30.9)		A/C	92 (49.7)	37 (36.3)	
				C/C	21 (11.4)	13 (12.7)	
C1105T							
C	293 (79.2)	169 (82.8)	0.29	C/C	113 (61.1)	67 (65.7)	0.218
T	77 (20.8)	35 (17.2)		C/T	67 (36.2)	35 (34.3)	
				T/T	5 (2.7)	0 (0.0)	
G4257A							
G	224 (60.5)	144 (70.6)	0.016	G/G	64 (34.6)	50 (49.0)	0.043
A	146 (39.5)	60 (29.4)		G/A	96 (51.9)	44 (43.1)	
				A/A	25 (13.5)	8 (7.8)	

35	Tsunemi, et al	2002	Japan	Case-control	Cases: 164 Controls: 100		**Genotype frequencies of the 1188A/C SNP of IL12B**

Genotype	AD (n=164)	Control (n=100)
AA	25 (15.2)	28 (28.0)
AC	84 (51.2)	45 (45.0)
CC	55 (33.5)	27 (27.0)
	p=0.041	

Allele frequencies of the 1188A/C SPN of IL12B

Allele	AD (n=164)	Control (n=100)
A	134 (40.9)	101 (50.5)
C	194 (59.1)	99 (49.5)
	p=0.031	

36	Tsunemi, et al	2002	Japan	Case-control	Cases: 98/42 (M/F) Controls: 140	28.0 (13-51)	**Genotype frequencies of the three SNP sites (−426C>T, −384A>G, 67G>A) of the eotaxin gene** **Allele frequencies of the three SNP sites (−426C>T, −384A>G, 67G>A) of the eotaxin gene in AD patients and controls**
37	Callard, et al	2002	UK	Cohort	Total: 992	0	**Associations of flexural eczema and early infection with the R551polymorphism of the IL-4 receptor alpha chain (IL-4Rα)**
38	Kozma, et al	2002	Hungary	Case-control	Cases: 68/60 (M/F) Controls: 303	6.3 (3-18)	**Genotype and allele frequencies for RANTES −28 and −403, and MPC-1−2518**

SNP site	Genotype	AD (n=140)	Control (n=140)	χ^2	*P*
–426C>T	C/C	118 (84.3)	121 (86.4)	1.71	0.425
	C/T	21 (15.0)	16 (11.4)		
	T/T	1 (0.7)	3 (2.1)		
–384A>G	A/A	69 (49.3)	70 (50.0)	1.33	0.514
	A/G	58 (41.4)	62 (44.3)		
	G/G	13 (9.3)	8 (5.7)		
67G>A	G/G	118 (84.3)	110 (78.6)	5.75	0.056
	G/A	19 (13.6)	30 (21.4)		
	A/A	3 (2.1)	0 (0.0)		

SNP site	Allele	AD (n=140)	Control (n=140)	χ^2	*P*
–426C>T	C allele	257 (91.8)	258 (92.1)	0.024	0.876
	T allele	23 (8.2)	22 (7.9)		
–384A>G	A allele	196 (70.0)	202 (72.1)	0.313	0.576
	G allele	84 (30.0)	78 (27.9)		
67G>A	G allele	255 (91.1)	250 (89.3)	0.504	0.478
	A allele	25 (8.9)	30 (10.7)		

Flexural eczema		IL-4Rα genotype			
	Prevalence	WT/WT prevalence	WT/R551 prevalence	R551/R551 prevalence	*P* *
Child had rash in joints and creases					
0-6 months % (n)	24.6 (245/994)	22.8 (137/602)	26.3 (89/339)	35.8 (19/53)	0.08
6-18 months % (n)	27.9 (271/970)	28.3 (168/593)	27.8 (91/327)	24.0 (12/50)	0.84
18-30 months % (n)	29.9 (279/934)	30.5 (174/571)	29.6 (93/314)	24.5 (12/49)	0.71
30-42 months % (n)	25.4 (234/921)	26.9 (152/566)	22.5 (69/307)	27.1(13/48)	0.34
Early infection					
Antibiotics use in first 6 months % (n)	34.1 (341/999)	32.8 (198/604)	35.0 (119/340)	43.6 (24/55)	0.25
Flexural eczema between birth and 6months					
Not given antibiotics (0-6 months)		21.7 (88/405)	26.8 (59/220)	43.3 (13/30)	0.02
Given antibiotics (0-6 months)		25.0 (49/196)	25.4 (30/118)	26.1 (6/23)	0.99

Polymorphism	Population	Genotype 11*	12*	22*	Total	Allele 2 frequencies
RANTES −28 C/G						
	AEDS	120	8	0	128	3.1
	Controls	284	19	0	303	3.1
RANTES −403 G/A						
	AEDS	86	38	4	128	18.0
	Controls	211	84	8	303	16.5
MCP-1 −2518 A/G						
	AEDS	83	35	10	128	21.5
	Controls	194	90	19	303	21.1

*1=frequent allele; 2=rare allele

39	Lee, et al	2001	Korea	Case-control	Cases: 28/25 (M/F) Controls: 184	18.9 (5-45)

Distribution of TAP1 alleles in atopic dermatitis patients

	Patients (n=53)		Controls (n=184)		RR		
	n	(%)	n	(%)	(95% CI)	P-value	Pc-value
Genotype frequencies							
TAP1*A/TAP1*A	34	(64.2)	113	(61.4)		NS	NS
TAP1*C/TAP1*C	0	(0.0)	1	(0.5)		NS	NS
TAP1*B/TAP1*B	2	(3.8)	4	(2.2)		NS	NS
TAP1*B/TAP1*C	1	(1.9)	6	(3.3)		NS	NS
TAP1*A/TAP1*C	2	(3.8)	11	(6.0)		NS	NS
TAP1*A/TAP1*B	14	(26.4)	49	(26.6)		NS	NS
Phenotype frequencies							
TAP1*A	50	(94.3)	173	(94.0)		NS	NS
TAP1*B	17	(34.0)	59	(32.1)		NS	NS
TAP1*C	3	(5.7)	18	(9.8)		NS	NS
Allele frequencies	(2n=106)		(2n=368)				
TAP1*A	84	(79.2)	286	(77.7)		NS	NS
TAP1*B	19	(17.9)	63	(17.1)		NS	NS
TAP1*C	3	(2.8)	19	(5.2)		NS	NS

Distribution of TAP2 alleles in atopic dermatitis patients

	Patients (n=53)		Controls (n=184)		RR		
	n	(%)	n	(%)	(95% CI)	P-value	Pc-value
Genotype frequencies							
TAP2*A/TAP2*A	10	(18.9)	35	(19.0)		NS	NS
TAP2*A/TAP2*B	13	(24.5)	66	(35.9)		NS	NS
TAP2*A/TAP2*C	10	(18.9)	8	(4.3)	5.1163 (2.01-12.45)	0.002	0.028
TAP2*A/TAP2*E	3	(5.7)	9	(4.9)		NS	NS
TAP2*B/TAP2*B	6	(11.3)	17	(9.2)		NS	NS
TAP2*B/TAP2*E	3	(5.7)	12	(6.5)		NS	NS
TAP2*B/TAP2*G	0	(0.0)	3	(1.6)		NS	NS
TAP2*C/TAP2*C	1	(1.9)	1	(0.5)		NS	NS
TAP2*C/TAP2*D	0	(0.0)	2	(1.1)		NS	NS
TAP2*D/TAP2*E	0	(0.0)	1	(0.5)		NS	NS
TAP2*E/TAP2*E	1	(1.9)	1	(0.5)		NS	NS
TAP2*A/TAP2*G or TAP2*B/TAP2*C[1]	5	(9.4)	22	(12.0)		NS	NS
TAP2*B/TAP2*D or TAP2*E/TAP2*G[1]	1	(1.9)	4	(2.2)		NS	NS
TAP2*A/TAP2*D or TAP2*C/TAP2*E[1]	0	(0.0)	3	(1.6)		NS	NS
Phenotype frequencies							
TAP2*A	36	(67.9)	118	(64.1)		NS	NS
TAP2*B	22	(41.5)	98	(53.3)		NS	NS
TAP2*C	11	(20.8)	11	(6.0)	4.1190 (1.76-9.63)	0.003	0.027
TAP2*D	0	(0.0)	3	(1.6)		NS	NS
TAP2*E	7	(13.2)	23	(12.5)		NS	NS
TAP2*G	0	(0.0)	3	(1.6)		NS	NS
Allele frequencies	(2n=106)		(2n=368)				
TAP2*A	46	(43.4)	153	(41.6)		NS	NS
TAP2*B	28	(26.4)	115	(31.3)		NS	NS
TAP2*C	12	(11.3)	12	(3.3)	3.7872 (1.73-8.28)	0.003	0.027
TAP2*D	0	(0.0)	3	(0.8)		NS	NS
TAP2*E	8	(7.5)	24	(6.5)		NS	NS
TAP2*G	0	(0.0)	3	(0.8)		NS	NS

Distribution of LMP2 alleles in atopic dermatitis patients

	Patients (n=53)		Controls (n=184)		RR		
	n	(%)	n	(%)	(95% CI)	P-value	Pc-value
Genotype frequencies							
LMP2*R/LMP2*R	32	(60.4)	113	(61.4)		NS	NS
LMP2*R/LMP2*H	20	(37.7)	64	(34.8)		NS	NS
LMP2*H/LMP2*H	1	(1.9)	7	(3.8)		NS	NS
Phenotype frequencies							
LMP2*R	52	(98.1)	173	(96.2)		NS	NS
LMP2*H	21	(39.6)	71	(38.6)		NS	NS
Gene frequencies	(2n=106)		(2n=368)				
LMP2*R	84	(79.2)	290	(78.8)		NS	NS
LMP2*H	22	(20.8)	78	(21.2)		NS	NS

Distribution of LMP7 alleles in atopic dermatitis patients

	Patients (n=53)		Controls (n=184)		RR		
	n	(%)	n	(%)	(95% CI)	P-value	Pc-value
Genotype frequencies							
LMP7*A/LMP7*A	9	(17.0)	26	(14.1)		NS	NS
LMP7*A/LMP7*B	27	(50.9)	78	(42.4)		NS	NS
LMP7*B/LMP7*B	14	(26.4)	56	(30.4)		NS	NS
LMP7*B/LMP7*C	2	(3.8)	16	(8.7)		NS	NS
LMP7*C/LMP7*C	0	(0.0)	1	(0.5)		NS	NS
LMP7*D/LMP7*X	1	(1.9)	7	(3.8)		NS	NS
Phenotype frequencies							
LMP7*A	36	(67.9)	104	(56.5)		NS	NS
LMP7*B	43	(81.1)	150	(81.5)		NS	NS
LMP7*C	2	(3.8)	17	(9.2)		NS	NS
LMP7*D	1	(1.9)	7	(3.8)		NS	NS
Allele frequencies	(2n=106)		(2n=368)				
LMP7*A	45	(42.5)	130	(35.3)		NS	NS
LMP7*B	57	(53.8)	206	(56.0)		NS	NS
LMP7*C	2	(1.9)	16	(4.3)		NS	NS
LMP7*D	0	(0.0)	0	(0.0)		NS	NS

40	Arkwright, et al	2001	UK	Case-control	Cases: 37/31 (M/F) Controls: 27/23 (M/F)	10±4 8±5

TGFB1 and IL10 polymorphism frequencies in children with and wihtout AD

	Control subjects (n=50)	Patients with AD (n=68)	P value*
TGFB1 polymorphisms, codon 25 (+915)			
Alle frequencies			
G	94 (94%)	109 (80%)	.004
C	6 (6%)	27 (20%)	
Genotype frequencies			
G/G	**44 (88%)**	**41 (60%)**	.001
G/C	6 (12%)	27 (40%)	
C/C	0 (0%)	0 (0%)	
TGFB1 polymorphisms, codon 10 (+869)			
Alle frequencies			
T	63 (63%)	91 (67%)	.5
C	37 (37%)	45 (33%)	
Genotype frequencies			
T/T	**25 (50%)**	**37 (54%)**	.9
T/C	13 (26%)	17 (25%)	
C/C	12 (24%)	14 (21%)	
IL10 polymorphism (−1082)			
Alle frequencies			
G	48 (48%)	62 (46%)	.8
A	52 (52%)	74 (54%)	
Genotype frequencies			
G/G	**13 (26%)**	**16 (24%)**	.9
G/A	21 (42%)	30 (44%)	
A/A	16 (32%)	22 (32%)	

TGFB1 (codon 25) polymorphism frequencies in control subjects, patients with mild-to-moderate AD (<30% of surface area affeced), and patients with severe AD (≥ 30% of surface area affeced)

	Control subjects (n=50)	Patients with mild-to-moderate AD (n=33)	Patients with severe AD (n=35)	P-value*
TGFB1 polymorphisms, codon 25 (+915)				
Allele frequencies				
G	94 (94%)	55 (83%)	54 (77%)	.003
C	6 (6%)	11 (17%)	16 (23%)	
Genotype frequencies				
G/G	**44 (88%)**	**22 (67%)**	**19 (54%)**	.002
G/C	6 (12%)	11 (33%)	16 (46%)	
C/C	0 (0%)	0 (0%)	0 (0%)	

41	Pascale, et al	2001	Italia	Case-control	Cases: 36/34 (M/F) Controls: 55/45 (M/F)	6.2 (1-12) 9.4 (5-15)

Genotype and allele distribution of the *Bst* XIMCC polymorphism in Itarlian patients

		Genotype			p	Odds ratio	95% CI	Allele		p	Odds ratio	95% CI
		AA	AB VS	BB				A	B			
Controls	100	25 (0.25)	51 (0.51)	24 (0.24)				101 (0.51)	99 (0.49)			
Asthma	50	9 (0.18)	28 (0.56)	13 (0.26)	0.94	1.11	0.46-2.58	46 (0.46)	54 (0.54)	0.54	1.20	0.72-2
AD	70	19 (0.27)	34 (0.49)	17 (0.24)	0.89	1.01	0.46-2.19	72 (0.51)	68 (0.49)	0.95	0.96	0.61-1.52

42	Liu, et al	2000	Germany	Nested case-control	Cases: 187 Controls: 98

Genotypic distribution of the IL13 4257G/A polymorphism

Phenotype	AA	AG	GG	Pearson χ^2 test (P value)	Fisher exact test P value	OR (95% CI)†
High IgE	6	42	52	10.97 (.004)	.003	2.38 (1.35-4.21)
Low IgE	1	30	80			
AD	10	72	105	5.67 (.059)	.057	1.77 (1.06-2.96)
Non-AD	6	24	68			

43	Oiso, et al	2000	Japan	Case-control	Cases: 27 Controls: 29	28.6 (15-63) 30.4 (22-71)	**Genotypes at IL-4R codons 50, 375, 406, 411, 551 and 761**

	No.				P-value
Genotype at codon 50		Ile/Ile	Ile/Val	Val/Va	
Atopic dermatitis	27	6	11	10	0.76
Non-atopic dermatitis	27	8	10	9	
Genotype at codon 375		Glu/Glu	Glu/Ala	Ala/Ala	
Atopic dermatitis	26	25	1	0	0.63
Non-atopic dermatitis	29	26	3	0	
Genotype at codon 406		Cys/Cys	Cys/Arg	Arg/Arg	
Atopic dermatitis	26	25	1	0	0.61
Non-atopic dermatitis	29	26	3	0	
Genotype at codon 411		Ser/Ser	Ser/Leu	Leu/Leu	
Atopic dermatitis	26	26	0	0	
Non-atopic dermatitis	29	29	0	0	
Genotype at codon 551		Glu/Glu	Glu/Arg	Arg/Arg	
Atopic dermatitis	27	21	6	0	0.01
Non-atopic dermatitis	28	28	0	0	
Genotype at codon 761		Ser/Ser	Ser/Pro	Pro/Pro	
Atopic dermatitis	25	25	0	0	
Non-atopic dermatitis	29	29	0	0	

44	Nickel, et al	2000	Germany	Nested case-control	Cases: 188 Controls: 98		**Distribution of RANTES pormoter genotypes in children**

	Genotype				
Subjects	AA	AG	GG	Frequency of A	P
AD (n=188)	6	72	110	0.22	0.037
Control subjects (n=98)	0	28	70	0.14	

45	Kawashima ,et al	1998	Japan	Case-control	Cases: 100 Controls: 101	11.1 (4-38) 12-13	**Genotype and allele distribution of the MCC-1903A/G polymorphism**

		Genotype			P[1]	Odds ratio	Allele		P	Odds ratio
		AA	AB	BB		(95% CI)[2]	A	B		(95% CI)
Controls	101	6 (0.06)	31 (0.31)	64 (0.63)			43 (0.21)	159 (0.79)		
AD	100	4 (0.04)	30 (0.30)	64 (0.66)	0.81	1.12 (0.63-1.99)	38 (0.20)	162 (0.80)	0.65	1.15 (0.71-1.87)

The A allele corresponds to - 1903 A and the B allele corresponds to -1903 G

[1] Comparisons were made between the BB genotype versus the other genotypes between the cases and controls by $2\times2\chi^2$ test,one tailed.

[2] Odds ratios (95% confidence interval) of the BB genotype associated with AD.

46	Kawashima, et al	1998	Japan	Case-control	Cases: 210 Controls: 215	10 (1-38) 11	**Genotypic and allelic distributions of the IL4 -590C/T polymorphism**

		Genotype			*Allele*	
	No	*CC*	*CT*	*TT*	*C*	*T*
Controls	215	17 (0.08)	97 (0.45)	101 (0.47)	131 (0.30)	299 (0.70)
AD parents	122	7 (0.06)	57 (0.47)	58 (0.48)	71 (0.29)	173 (0.71)
AD offspring	88	8 (0.09)	25 (0.28)	55 (0.63)	41 (0.23)	135 (0.77)
Odds ratio		1.16	0.48	1.88		1.44
95% condifidence interval		0.52-2.78	0.29-0.83	1.13-3.09		0.69-2.14
p value		0.73	0.007	0.01		0.08

47	Ismaïl, et al	1997	Tunisia	Case-control	Cases: 20 Controls: 52/29 (M/F)	10 24	**TAP1 gene and allele frequencies (%)**

	Codon		Control group (2n=162)	AD Group (2n=40)	
	333	637	%	%	p value
a	Val		11	25	0.01
b	Ile		89	75	
c		Asp	86	62	
d		Gly	14	32	0.005
A	Ile	Asp	84	62	0.0008
B	Val	Gly	9	25	0.005
C	Val	Asp	2	0	NS
D	Ile	Gly	5	13	NS

Distribution (%) of TAP1 genetypes

	Control group (n=81)	AD group (n=20)	
Genotype	%	%	p value
a/a	2	10	NS
a/b	18	30	NS
d/d	4	15	0.01
c/d	20	45	0.0003
A/A	73	40	0.0001
A/B	12	25	0.03
A/C	2	0	NS
A/D	6	20	0.006
B/B	0	10	0.004
B/C	2	0	NS
B/D	4	5	NS
C/C	0	0	NS
C/D	0	0	NS
D/D	0	0	NS

48	Kuwata, et al	1996	Japan	Case-control	Cases: 27/10 (M/F) Controls: 52	27.0 (11-42)	**HLA-DM allele frequencies**

HLA-DM alleles	Atopic dermatitis (n=74)	Control (n=104)	Relative Risk	Chi-square	p Value
DMA					
0101	66 (89%)	93 (89%)	0.98	0.002480	0.9602
0102	7 (9%)	11 (11%)	0.88	0.05939	0.8074
0103	1 (1%)	0 (0%)	4.27	0.02940	0.8638
DMB					
0101	41 (55%)	52 (50%)	1.24	0.5063	0.4767
0102	21 (28%)	29 (28%)	1.02	0.005218	0.9424
0103	12 (16%)	23 (22%)	0.68	0.9524	0.3290

49	Mao, et al	1996	Japan	Case-control	Cases: 100 Controls: 100		**Association between genotypes of proteases on chromosome 14 and atopic diseases**

Individual groups	Number of cases	CGL (Mboll)					MCC (BstXI)				
		AA	AB	BB	p	Odds ratio (95% CI)	AA	AB	BB	p	Odds ratio (95% CI)
Control	100	2	38	60	··	··	9	38	53	··	··
Eczema	100	5	34	61	0.89	1.04 (0.60-1.80)	3	26	71	0.009	2.17 (1.21-3.88)
Atopic rhinitis	100	5	38	57	0.67	0.88 (0.50-1.55)	4	38	58	0.47	1.22 (0.70-2.11)
Atopic asthma	100	4	32	64	0.56	1.19 (0.66-2.13)	8	39	53	1.00	1.00
Non-atopic asthma	100	3	30	67	0.31	1.35 (0.76-2.38)	1	34	65	0.085	1.64 (0.93-2.88)

Table 2. Genetic factors in relation to atopic dermatitis

GZMB [CGL1] (Mbo II)	-49			
CMA1	↑ 49	-45	-41	↓ 5
HLA-DMA	-48			
HLA-DMB	-48			
TAP1 (position 333, position 637)	↑ 47	-39		
IL4 -590C/T	↓ 46	-20		
CCL5 [RANTES] promoter -401A/G	-44			
IL4R Ile50Val	-43			
IL4R Glu375Ala	-43			
IL4R Cys406Arg	-43			
IL4R Ser411Leu	-43			
IL4R Glu551Arg	↑ 43	↑ 37 (only not given antibiotics)		
IL4R Ser761Pro	-43			
IL13 G4257A	↑ 42	↑ 34		
TGFB1, codon 25 (+915G>C)	↑ 40			
TGFB1, codon 10 (+869C>T)	-40			
IL10 -1082G>A	-40	-29		
TAP2 (position 379, 565, 665)	↑ 39			
PSMB9 [LMP2] (position 60)	-39			
PSMB8 [LMP7] (position 3911, 3912, 4069)	-39			
MCP1 -2518A/G	-38			
CCL5 [RANTES] -28G/C	-38			
CCL5 [RANTES] -403G/A	-38			
CCL11 [eotaxin gene]	-36			
IL12B 1188A/C	↑ 35			
IL13 A704C	-34			
IL13 C1103T	-34			
CD14 C-159T	-33	↓ 18	↓ 7	
CARD15 C2104T	-32			
CARD15 G2722C	↑ 32			
CARD15 3020iC	-32			
SPINK5 IVS12-26C/T	↓ 31			
SPINK5 IVS12-10A/G	↓ 31			

SPINK5 1103A/G	↓31	
SPINK5 1156G/A	-31	
SPINK5 1188T/C	↓31	
SPINK5 1258G/A	↓31	-19(↑:sum of AD amd asthma)
STAT6 2964G/A	-30	
TNFA -238G/A	-29	
TNFA -308G/A	-29	-27
IL6 -174C/G	-29	
IL1B -511T/C	-29	
IL1B +3953T/C	-29	-27
IL1RN intron 2	-29	
IL13 Arg130Glu	↑28	
IL13 C-1112T	-28	
IL14 C-589T	-28	
CSF2 [GM-CSF] -677C/A	↑27	
CSF2 [GM-CSF] -1916T/C	↑27	
NAT2 C481T, G590A, G87A haplotype	-26	
GSTP1 Ile105Val	↓25	-21
IL5 -703C/T	-24	
CCR3 T51C	-23	
IL13 -1024C/T	↑22	
GSTM1	-21	
GSTT1	-21	
GSTM1, GSTT1, GSTP1 haplotype	↑21	
CTLA4 49A/G	-20	
TLR2 R753Q	-17	
TLR4 D299G T399I	-17	
TLR2 or TLR4	↑17	
IL4R -3112C>T	↑16	
IL4R -1803T>C	↑16	
IL4R -327C>A	↑16	
IL4R -326A>C	↑16	
IL4R -186G>A	↑16	
IL4R -184A>G	-16	

KLK7 [SCCE] AACC insertion	↑15
CCRN4L [CCR4] C1014T	-14
CCL17 [TARC] -431C>T	-13
SLC9A3R1-NAT9 RUNX1 binding site	-12
IL18 113G	-11
IL18 127T	-11
IL18 -137C	↑11
IL18 -132G	-11
IL18 -133G	-11
SPINK5 Asn368Ser	-10
SPINK5 Asp386Asm	-10
SPINK5 Glu420Lys	-10
NOD1 haplotypes	↓9
IL1RL1 -26999G/A	↓6
IL1RL1 haplotype (-26999-27639)	↓6
IL12RB1 -111A/T	↓4
IL12RB1 -2C/T	↓4
TLR6 Ser249Pro	-3
NAT2 C481T	-2
NAT2 G590A	-2
NAT2 C481T and G590A	↑2
MBL2 codon54	-1
CARD15 rs5743266	-8
CARD15 rs2067085	-8
CARD15 rs2066842	-8
CARD15 rs2066844	-8
CARD15 rs2066845	-8
CARD15 rs5743291	-8
CARD15 rs1077861	-8
CARD15 rs3135500	-8

表中の番号は文献番号である。

Ⅲ．研究成果の刊行一覧・別冊

研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miyake Y, Sasaki S, Ohya Y, Miyamoto S, Matsunaga I, Yoshida T, Hirota Y, Oda H; The Osaka Maternal And Child Health Study Group	Dietary intake of seaweed and minerals and prevalence of allergic rhinitis in Japanese pregnant females: baseline data from the Osaka Maternal and Child Health Study	Ann Epidemiol	16(8)	614-621	2006
Miyamoto S, Miyake Y, Sasaki S, Tanaka K, Ohya Y, Matsunaga I, Yoshida T, Oda H, Ishiko O, Hirota Y; Osaka Maternal and Child Health Study Group	Fat and fish intake and asthma in Japanese women: baseline data from the Osaka Maternal and Child Health Study	Int J Tuberc Lung Dis	11(1)	103-109	2007
Miyake Y, Sasaki S, Yokoyama T, Tanaka K, Ohya Y, Fukushima W, Saito K, Ohfuji S, Kiyohara C, Hirota Y; Osaka Maternal and Child Health Study Group	Risk of postpartum depression in relation to dietary fish and fat intake in Japan: the Osaka Maternal and Child Health Study	Psychol Med	36(12)	1727-1735	2006
Miyake Y, Sasaki S, Tanaka K, Yokoyama T, Ohya Y, Fukushima W, Saito K, Ohfuji S, Kiyohara C, Hirota Y; Osaka Maternal and Child Health Study Group	Dietary folate and vitamins B_{12}, B_6, and B_2 intake and the risk of postpartum depression in Japan: the Osaka Maternal and Child Health Study	J Affect Disord	96(1-2)	133-138	2006
Tanaka K, Miyake Y, Sasaki S, Ohya Y, Miyamoto S, Matsunaga I, Yoshida T, Hirota Y, Oda H, The Osaka Maternal and Child Health Study Group	Magnesium intake is inversely associated with the prevalence of tooth loss in Japanese pregnant women: the Osaka Maternal and Child Health Study	Magnes Res	19(4)	268-275	2006

Miyake Y, Sasaki S, Tanaka K, Ohya Y, Miyamoto S, Matsunaga I, Yoshida T, Hirota Y, Oda H, The Osaka Maternal and Child Health Study Group	Fish and fat intake and prevalence of allergic rhinitis in Japanese females: the Osaka Maternal and Child Health Study	J Am Coll Nutr		In press	
Miyake Y, Ohya Y, Tanaka K, Yokoyama T, Sasaki S, Fukushima W, Ohfuji S, Saito K, Kiyohara C, Hirota Y, The Osaka Maternal and Child Health Study Group	Home environment and suspected atopic eczema in Japanese infants: The Osaka Maternal and Child Health Study	Pediatr Allergy Immunol		In press	
Miyake Y, Arakawa M, Tanaka K, Sasaki S, Ohya Y	Cross-sectional study of allergic disorders associated with breastfeeding in Japan: The Ryukyus Child Health Study	Pediatr Allergy Immunol		In press	